Comparison of ARCA biopharma Inc. (ABIO) and Nightstar Therapeutics plc (NASDAQ:NITE)

As Biotechnology companies, ARCA biopharma Inc. (NASDAQ:ABIO) and Nightstar Therapeutics plc (NASDAQ:NITE) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ARCA biopharma Inc. N/A 0.00 10.64M -0.82 0.00
Nightstar Therapeutics plc N/A 0.00 42.26M -1.93 0.00

Demonstrates ARCA biopharma Inc. and Nightstar Therapeutics plc earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
ARCA biopharma Inc. 0.00% -112.6% -97.5%
Nightstar Therapeutics plc 0.00% -38.7% -35.1%

Liquidity

The Current Ratio of ARCA biopharma Inc. is 8.6 while its Quick Ratio stands at 8.6. The Current Ratio of rival Nightstar Therapeutics plc is 7.7 and its Quick Ratio is has 7.7. ARCA biopharma Inc. is better equipped to clear short and long-term obligations than Nightstar Therapeutics plc.

Institutional and Insider Ownership

The shares of both ARCA biopharma Inc. and Nightstar Therapeutics plc are owned by institutional investors at 15% and 49.8% respectively. About 1.17% of ARCA biopharma Inc.’s share are owned by insiders. Insiders Comparatively, owned 40.63% of Nightstar Therapeutics plc shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ARCA biopharma Inc. -1.2% -36.25% -10.08% -2.02% -59.24% -62.26%
Nightstar Therapeutics plc -12.92% 23.65% -46.32% -7.57% -23.12% -0.38%

For the past year Nightstar Therapeutics plc has weaker performance than ARCA biopharma Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.